ImmunityBio (IBRX) vs Twist Bioscience (TWST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Twist Bioscience (TWST) has outperformed ImmunityBio (IBRX) over the past year, gaining 406.7% versus a gain of 290.4%. Over five years, TWST leads with a +38.0% price change compared with +4.8% for IBRX. ImmunityBio is the larger company by market cap ($10.33 billion vs $10.32 billion), about 1.0 times the size.
Twist Bioscience converts more of its revenue into profit, with a net margin of -20.6% versus -310.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBRX | TWST |
|---|---|---|
| Share price | $9.75 | $155.65 |
| Market cap | $10.33B | $10.32B |
| 1-day change | +0.62% | -6.78% |
| YTD return | +392.93% | +397.16% |
| 1-year return | +290.40% | +406.75% |
| 5-year return | +4.84% | +37.99% |
| EPS (TTM) | $-0.97 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $113.29M | $376.57M |
| Revenue growth (YoY) | +668.31% | +20.32% |
| Net income (latest FY) | $-351.40M | $-77.67M |
| Gross margin | 99.34% | 50.72% |
| Operating margin | -226.00% | -36.18% |
| Net margin | -310.18% | -20.63% |
| 52-week high | $12.43 | $219.71 |
| 52-week low | $1.95 | $23.30 |
| Distance from 52-week high | -21.56% | -29.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +30.77% | -14.07% |
| Average volume | 10.26M | 1.92M |
| Shares outstanding | 1.06B | 66.30M |
| Employees | 684 | 979 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TWST has outperformed IBRX by 116.3 percentage points over the past year.
- Twist Bioscience is more profitable, keeping -20.6 cents of every revenue dollar as net income versus -310.2 cents for ImmunityBio.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +20.32%).
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
About Twist Bioscience
TWST stock →Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 979 employees
IBRX vs TWST FAQ
Which is bigger, ImmunityBio or Twist Bioscience?
ImmunityBio (IBRX) is larger, with a market capitalization of $10.33B compared with $10.32B for Twist Bioscience (TWST).
Which stock has performed better over the past year, IBRX or TWST?
TWST returned +406.75% over the past 12 months, compared with +290.40% for IBRX (price return, excluding dividends). Past performance does not predict future results.
Are ImmunityBio and Twist Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.